Q-omics provides the consensus-scored TIGD5 profile across patient tissues and cancer cell-line models. TIGD5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TIGD5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TIGD5 RNA expression shows 18,513 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where TIGD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD5 survival associations across molecular data types. TIGD5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD5 RNA expression–survival associations across cancer types. High TIGD5 expression shows unfavorable associations in LIHC, UVM, ACC, CESC, KICH and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TIGD5 RNA expression.
This table summarizes TIGD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TIGD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD5 shows higher tumor expression in HNSC, COAD, KIRC, KIRP, LIHC and KICH. The HNSC box plot shows higher TIGD5 RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with TIGD5 in patient tissues and cancer cell lines. In patient samples, TIGD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
